FORM 10-K (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36274 Intra-Cellular Therapies, Inc. (Exact name of registrant as specified in its charter) Delaware 36-4742850 (S ...

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Juan Sanchez - VP, Corporate Communications & IR Sharon Mates - Co-Founder, Chairman, CEO & President Mark Neumann - EVP & Chief Commercial Officer Andrew Satlin - EVP & Chief Medical Officer Lawrence Hineline - SVP, Finance, CFO, Treasurer and Assistant Secretary Conference Call Participants Charles Duncan - Cantor Fitzgerald Jessica Fye - JPMorgan Chase & Co. Andrew Tsai - Jefferi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36274 INTRA-CELLULAR THERAPIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-4 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact name of registrant as specified in its charter) Delaware 36-4742850 (State or other jurisdiction of incorporation or organization) ...

Intra-Cellular Therapies, Inc (NASDAQ:ITCI) Q1 2019 Earnings Conference Call May 8, 2019 8:30 AM ET Company Participants Juan Sanchez – Vice President of Investor Relations Sharon Mates – Chairman and Chief Executive Officer Mark Neumann – Executive Vice President and Chief Commercial Officer Andrew Satlin – Executive Vice President and Chief Medical Officer Larry Hineline – Senior Vice President and Chief Financial Officer Kimberly Vanover – Senior Vice President of Early Stage Clinical Development and Tra ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36274 INTRA-CELLULAR THERAPIES, INC. (Exact name of registrant as specified in its charter) Delaware 36-47428 ...

Intra-Cellular T H E R A P I E S Corporate Presentation Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements concern our product candidates, our development efforts, our collaborations, our technology, our intellectual property, our financial condition, our plans and our development programs. These statements involve risks, uncertainties and assumptions, and are based on the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36274 Intra-Cellular Therapies, Inc. (Exact name of registrant as specified in its charter) Delaware 36-4742850 (S ...